4 March 2010
Cardiff, UK: Q Chip Ltd, the biopharmaceutical company developing sustained release biotherapies, is pleased to announce that it has appointed Dr Tony Mills to its Board of Directors. Tony brings a wealth of experience in commercialising technology in the biopharmaceutical sector and as Chief Commercial Officer, will be responsible for generating revenues from Q Chip’s proprietary technology, Q-SpheraTM.

Tony has over 20 years experience in intellectual property (IP) management and biotech commercialisation. After training as a virologist he worked in the vaccine industry for several years before joining the IP development company, BTG, where he licensed vaccine related IP worldwide. Tony was a key member of the team that founded Peptide Therapeutics, acquired as Acambis in 2008 by Sanofi Aventis for £280 million. More recently Tony has continued his interest in the commercialisation of biotech as VP Business Development at BioVex, followed by a role as an Executive Director of Phynova, the Oxford based company deriving novel drug candidates from plants.

“We are delighted with this appointment” said Executive Chairman Ken Powell, “Tony brings invaluable commercial experience and expertise and we are looking forward to his contribution to Q Chip’s commercialisation plans”.